

## WHAT IS CLAIMED IS:

1. An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding VCC-1, wherein said antisense compound specifically hybridizes with and inhibits the expression of VCC-  
5 1.
2. The antisense compound of claim 1 which is an antisense oligonucleotide.
3. The antisense oligonucleotide of claim 2 comprising a nucleic acid sequence selected from the group consisting of at least eight contiguous bases of  
10 SEQ ID NO:1 – SEQ ID NO:1099.
4. The antisense oligonucleotide of claim 2 comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:1 – SEQ ID NO:1099.
5. The antisense compound of claim 2, 3, or 4 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.  
15
6. The antisense compound of claim 5 wherein the modified internucleoside linkage is a phosphorothioate linkage.
7. The antisense compound of claim 2, 3, or 4 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
- 20 8. The antisense compound of claim 7 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
9. The antisense compound of claim 2, 3, or 4 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
- 25 10. The antisense compound of claim 9 wherein the modified nucleobase is a 5-methylcytosine.
11. The antisense compound of claim 2, 3, or 4 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

12. A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

13. The composition of claim 12 further comprising a colloidal dispersion system.

5 14. The composition of claim 13 wherein the antisense compound is an antisense oligonucleotide.

15. A method of inhibiting the expression of VCC-1 in cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of VCC-1 is inhibited.

10 16. A method of treating a human having a disease or condition associated with VCC-1 comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 1 so that expression of VCC-1 is inhibited.

17. The method of claim 16 wherein the disease or condition is  
15 diabetes.

18. The method of claim 16 wherein the disease or condition is an immunological disorder.

19. The method of claim 16 wherein the disease or condition is a cardiovascular disorder.

20 20. The method of claim 16 wherein the disease or condition is a neurologic disorder.

21. The method of claim 16 wherein the disease or condition is ischemia/reperfusion injury.

22. The method of claim 16 wherein the disease or condition is any  
25 form of cancer.

23. The method of claim 16 wherein the disease or condition is an angiogenic disorder.